VTGN vs. ACRV
VTGN (VistaGen Therapeutics, Inc.) and ACRV (Acrivon Therapeutics Inc. Common Stock) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, VTGN returned -28.22%/yr vs -50.76%/yr for ACRV. At a 0.25 correlation, their price movements are largely independent.
Performance
VTGN vs. ACRV - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, VTGN achieves a -4.47% return, which is significantly higher than ACRV's -32.37% return.
VTGN
- 1D
- -1.19%
- 1M
- -2.27%
- YTD
- -4.47%
- 6M
- -11.33%
- 1Y
- -67.74%
- 3Y*
- -28.22%
- 5Y*
- -61.91%
- 10Y*
- -40.14%
ACRV
- 1D
- 3.16%
- 1M
- -6.86%
- YTD
- -32.37%
- 6M
- -29.74%
- 1Y
- 38.14%
- 3Y*
- -50.76%
- 5Y*
- —
- 10Y*
- —
VTGN vs. ACRV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
VTGN VistaGen Therapeutics, Inc. | -4.47% | -77.56% | -42.61% | 66.34% | -32.68% |
ACRV Acrivon Therapeutics Inc. Common Stock | -32.37% | -59.97% | 22.36% | -57.29% | -13.71% |
Correlation
The correlation between VTGN and ACRV is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.30 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.27 |
Correlation (All Time) Calculated using the full available price history since Nov 15, 2022 | 0.25 |
Fundamentals
VTGN:
$24.07M
ACRV:
$63.12M
VTGN:
-$1.88
ACRV:
-$2.00
VTGN:
0.68
ACRV:
0.66
VTGN:
$1.27M
ACRV:
$0.00
VTGN:
$522.00K
ACRV:
$311.00K
VTGN:
-$68.97M
ACRV:
-$84.65M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
VTGN vs. ACRV — Risk / Return Rank
VTGN
ACRV
VTGN vs. ACRV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for VistaGen Therapeutics, Inc. (VTGN) and Acrivon Therapeutics Inc. Common Stock (ACRV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VTGN | ACRV | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.02 | ||
| Sortino ratioReturn per unit of downside risk | -1.28 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 1.17 | -0.17 |
| Calmar ratioReturn relative to maximum drawdown | -0.76 | 0.67 | -1.43 |
| Martin ratioReturn relative to average drawdown | -1.08 | 1.26 | -2.34 |
Loading charts...
Drawdowns
VTGN vs. ACRV - Drawdown Comparison
The maximum VTGN drawdown since its inception was -99.76%, roughly equal to the maximum ACRV drawdown of -95.47%. Use the drawdown chart below to compare losses from any high point for VTGN and ACRV.
Loading charts...
Drawdown Indicators
| VTGN | ACRV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.76% | -95.47% | -4.29% |
Max Drawdown (1Y)Largest decline over 1 year | -89.69% | -57.14% | -32.55% |
Max Drawdown (3Y)Largest decline over 3 years | -96.13% | -92.31% | -3.82% |
Max Drawdown (5Y)Largest decline over 5 years | -99.51% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -99.62% | — | — |
Current DrawdownCurrent decline from peak | -99.70% | -92.97% | -6.73% |
Average DrawdownAverage peak-to-trough decline | -84.48% | -70.67% | -13.81% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 62.61% | 30.37% | +32.24% |
Volatility
VTGN vs. ACRV - Volatility Comparison
VistaGen Therapeutics, Inc. (VTGN) has a higher volatility of 25.47% compared to Acrivon Therapeutics Inc. Common Stock (ACRV) at 14.33%. This indicates that VTGN's price experiences larger fluctuations and is considered to be riskier than ACRV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| VTGN | ACRV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 25.47% | 14.33% | +11.14% |
Volatility (6M)Calculated over the trailing 6-month period | 50.23% | 72.91% | -22.68% |
Volatility (1Y)Calculated over the trailing 1-year period | 112.86% | 92.04% | +20.82% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 320.41% | 104.09% | +216.32% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 240.09% | 104.09% | +136.00% |
Dividends
VTGN vs. ACRV - Dividend Comparison
Neither VTGN nor ACRV has paid dividends to shareholders.
Financials
VTGN vs. ACRV - Financials Comparison
This section allows you to compare key financial metrics between VistaGen Therapeutics, Inc. and Acrivon Therapeutics Inc. Common Stock. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
VTGN and ACRV have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
VTGN has higher volatility (25.47%) compared to ACRV (14.33%). In terms of maximum drawdown, VTGN dropped -99.76% vs ACRV's -95.47%.
ACRV currently has the higher Sharpe Ratio (0.42 vs -0.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for VTGN and ACRV
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer